Clinical trials: Newly Diagnosed Oligometastatic Prostate Cancer
Prostate Cancer
A Study of Definitive Therapy to Treat Prostate Cancer After Prostatectomy
To assess the safety of treating men with oligometastatic prostate cancer with the following therapy: (1st) Systemic chemo-hormonal therapy with up to 6-months (~24 weeks) of adjuvant androgen deprivation and up to 6 cycles of…
- Trial name
- NCT03043807
- Testing
- Leuprolide Acetate, Docetaxel, Bicalutamide
- Where
- 2 sites in United States
- Volunteers
- 26 people
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Newly Diagnosed Oligometastatic Prostate Cancer
Systemic and Tumor-Directed Therapy for Oligometastatic Prostate Cancer
This is a trial for patients with newly diagnosed metastatic prostate cancer with 5 or fewer sites of metastases. The trial involves surgery (removal of the prostate) or radiation to the prostate, six months of hormone therapy…
- Trial name
- NCT03298087
- Testing
- radical prostatectomy, stereotactic body radiotherapy, Leuprolide
- Where
- 3 sites in United States
- Volunteers
- 28 people
- Sponsor
- VA Office of Research and Development
Prostate Cancer
A Study of Definitive Therapy to Treat Prostate Cancer
To assess the safety of treating men with oligometastatic prostate cancer with the following therapy: (1st) Systemic chemo-hormonal therapy with up to 6-months (~24 weeks) of neoadjuvant androgen deprivation and up to 6 cycles of…
- Trial name
- oligo-mets (NCT02716974)
- Testing
- Leuprolide Acetate, Bicalutamide, Docetaxel
- Where
- 3 sites in United States
- Volunteers
- 26 people
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins